KYMR•benzinga•
B. Riley Securities Upgrades Kymera Therapeutics to Buy, Raises Price Target to $60
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 3, 2025 by benzinga